Tick borne encephalitis: Development of a paediatric vaccine. A controlled, randomized, double-blind and multicentre study

被引:33
作者
Girgsdies, OE [1 ]
Rosenkranz, G [1 ]
机构
[1] SANDOZ PHARMA LTD,CH-4002 BASEL,SWITZERLAND
关键词
tick-borne encephalitis; paediatric vaccine; clinical trial;
D O I
10.1016/S0264-410X(96)00081-3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A total of 522 children between 18 months and 14 years and 191 adults between 18 and 60 years were vaccinated with TEE-vaccine according to an abbreviated schedule (0, 7, 21). The aim of the study was to investigate whether reducing the amount of antigen in the vaccination for children would preserve an adequate immune response and decrease the rate of site-effects. Efficacy, was determined on the extent to which children, vaccinated with the low doses (0.4 mu g or 0.75 mu g), reacted by developing antibodies in the same way as adults treated with the approved dose of 1.5 mu g (equivalence of titres). The titres obtained in the children with the two lower doses were equivalent to those in the adults obtained with the standard dose. Titres decreased in the children with increasing age. Children older than 12 years in the approved dosage group had the same median titres as adults. The frequency of side-effects in the two lower dose groups, especially raised temperature was markedly reduced. Whereas 30.1% of the children vaccinated with the approved dose had raised temperature higher than 38 degrees C only 18.8% and 18.4%, respectively, of the children vaccinated with the lower doses developed such temperatures. This improved tolerance in terms of raised temperature was also reflected in the other general reactions such as tiredness, joint pain or headache. Copyright (C) 1996 Elsevier Science Ltd.
引用
收藏
页码:1421 / 1428
页数:8
相关论文
共 10 条
[1]   A NEW VACCINE AGAINST TICK-BORNE ENCEPHALITIS - INITIAL TRIAL IN MAN INCLUDING A DOSE-RESPONSE STUDY [J].
BOCK, HL ;
KLOCKMANN, U ;
JUNGST, C ;
SCHINDELKUNZEL, F ;
THEOBALD, K ;
ZERBAN, R .
VACCINE, 1990, 8 (01) :22-24
[2]   A RANDOMIZED PHASE-II STUDY OF A NEW TICK-BORNE ENCEPHALITIS VACCINE USING 3 DIFFERENT DOSES AND 2 IMMUNIZATION REGIMENS [J].
HARABACZ, I ;
BOCK, H ;
JUNGST, C ;
KLOCKMANN, U ;
PRAUS, M ;
WEBER, R .
VACCINE, 1992, 10 (03) :145-150
[3]   VACCINATION AGAINST TICK-BORNE ENCEPHALITIS (TEE) - INFLUENCE OF SIMULTANEOUS APPLICATION OF TEE IMMUNOGLOBULIN ON SEROCONVERSION AND RATE OF ADVERSE EVENTS [J].
HEDENSTROM, MV ;
HEBERLE, U ;
THEOBALD, K .
VACCINE, 1995, 13 (08) :759-762
[4]   A TOPOLOGICAL AND FUNCTIONAL-MODEL OF EPITOPES ON THE STRUCTURAL GLYCOPROTEIN OF TICK-BORNE ENCEPHALITIS-VIRUS DEFINED BY MONOCLONAL-ANTIBODIES [J].
HEINZ, FX ;
BERGER, R ;
TUMA, W ;
KUNZ, C .
VIROLOGY, 1983, 126 (02) :525-537
[5]   PREPARATION OF A HIGHLY PURIFIED VACCINE AGAINST TICK-BORNE ENCEPHALITIS BY CONTINUOUS-FLOW ZONAL ULTRA-CENTRIFUGATION [J].
HEINZ, FX ;
KUNZ, C ;
FAUMA, H .
JOURNAL OF MEDICAL VIROLOGY, 1980, 6 (03) :213-221
[6]  
HOFMANN G, 1989, BUNDESGESUNDHBL, V5, P183
[7]   PRECLINICAL INVESTIGATIONS OF THE SAFETY, IMMUNOGENICITY AND EFFICACY OF A PURIFIED, INACTIVATED TICK-BORNE ENCEPHALITIS VACCINE [J].
KLOCKMANN, U ;
BOCK, HL ;
FRANKE, V ;
HEIN, B ;
REINER, G ;
HILFENHAUS, J .
JOURNAL OF BIOLOGICAL STANDARDIZATION, 1989, 17 (04) :331-342
[8]  
PRAUS M, 1993, TOLERANCE IMMUNOGENI
[9]  
QUAST U, 1993, KINDERARZT, V24, P193
[10]  
ROGGENDORF M, 1995, DURCH ZECKEN UBERTRA, P7